{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:16:18Z","timestamp":1783332978648,"version":"3.54.6"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transdermal fentanyl is usually reserved for opioid-tolerant patients, but in Japan, a low-dose transdermal fentanyl patch (0.5\u00a0mg, delivering ~6\u00a0\u03bcg\/h; Fentos tape\u00ae) has been approved for opioid-na\u00efve cancer pain. However, real-world data on how this formulation is prescribed are limited. This study aimed to compare patient characteristics and prescribing reasons between opioid-na\u00efve and non-na\u00efve patients and to identify factors associated with opioid-na\u00efve initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 107 patients who were started on a low-dose transdermal fentanyl patch (0.5\u00a0mg, delivering ~6\u00a0\u03bcg\/h) at a Japanese university hospital. Patients were classified as opioid-na\u00efve [no prior opioid (n\u00a0=\u00a036)] or non-na\u00efve [switched (n\u00a0=\u00a071)]. Data on demographics, cancer type, department, care setting, and reasons for patch use were categorized. Multivariate logistic regression examined factors associated with opioid-na\u00efve initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Opioid-na\u00efve patients more often had gastrointestinal cancer and were managed by gastrointestinal (GI)-related departments. Age and inpatient status were similar between the groups. The distribution of reasons for prescribing did not significantly differ (oral intake difficulty, 39% vs. 42%; bowel problems, 14% vs. 10%; renal dysfunction, 8% vs. 4%). GI cancer (adjusted odds ratio [OR], 4.43; 95% confidence interval [CI], 1.75\u201311.18) and GI-related department (adjusted OR, 4.57; 95% CI, 1.67\u201312.53) were independently associated with opioid-na\u00efve initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this cohort, low-dose transdermal fentanyl patches were preferentially used as first-line strong opioids in patients with GI cancers and those under GI specialist care, rather than being limited to those with clear swallowing difficulty.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag053","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:38:18Z","timestamp":1773751098000},"page":"873-878","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and reasons for low-dose fentanyl patch use in opioid-na\u00efve versus non-na\u00efve patients with cancer pain"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4920-5130","authenticated-orcid":false,"given":"Shinya","family":"Kajiura","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Palliative Medicine, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]},{"name":"Palliative Care Team, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]},{"name":"Third Department of Internal Medicine, University of Toyama , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Chikaoka","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Palliative Medicine, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]},{"name":"Palliative Care Team, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Ueda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iori","family":"Motoo","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, University of Toyama , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Palliative Medicine, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]},{"name":"Palliative Care Team, Toyama University Hospital , 2630 Sugitani, Toyama-shi, Toyama-ken, 930-0194,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"2026070605421660100_ref1","volume-title":"WHO guidelines for the pharmacological and Radiotherapeutic Management of Cancer Pain in adults and adolescents","author":"World Health Organization (WHO)","year":"2018"},{"key":"2026070605421660100_ref2","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026070605421660100_ref3","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","article-title":"Management of cancer pain in adult patients: ESMO clinical practice guidelines","volume":"29","author":"Fallon","year":"2018","journal-title":"Ann Oncol"},{"key":"2026070605421660100_ref4","article-title":"Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults","volume":"CG140","author":"National Institute for Health and Care Excellence (NICE)","journal-title":"Clinical Guideline"},{"key":"2026070605421660100_ref5","article-title":"Drug safety update: transdermal fentanyl patches for non-cancer pain: do not use in opioid-na\u00efve patients","volume":"14","author":"Medicines and Healthcare products Regulatory Agency (MHRA)","year":"2020","journal-title":"MHRA"},{"key":"2026070605421660100_ref6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00228-018-2588-0","article-title":"A population-based study of transdermal fentanyl initiation in Australian clinical practice","volume":"75","author":"Gisev","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"2026070605421660100_ref7","article-title":"Fentos tape 0.5 mg [Japanese package insert]","author":"Pharmaceuticals and Medical Devices Agency (PMDA)","year":"2020. . 1\u20139","journal-title":"PMDA"},{"key":"2026070605421660100_ref8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40261-020-00965-9","article-title":"Efficacy and safety of fentanyl citrate patch, including a low-dose 0.5 mg formulation, in opioid-na\u00efve patients with cancer pain","volume":"40","author":"Yamaguchi","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2026070605421660100_ref9","article-title":"Fentos tape 0.5 mg [Japanese package insert and review report]","author":"Pharmaceuticals and Medical Devices Agency (PMDA)","year":"2020. . 1\u201322","journal-title":"PMDA"},{"key":"2026070605421660100_ref10","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1185\/03007995.2010.532545","article-title":"Low doses of transdermal fentanyl in opioid-naive patients with cancer pain","volume":"26","author":"Mercadante","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2026070605421660100_ref11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/DDDT.S414318","article-title":"Guidelines for rational clinical use of fentanyl transdermal patch","volume":"18","author":"Fu","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"2026070605421660100_ref12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.21037\/apm.2020.01.12","article-title":"Reasons to avoid fentanyl","volume":"9","author":"Davis","year":"2020","journal-title":"Ann Palliat Med"},{"key":"2026070605421660100_ref13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3904\/kjim.2015.30.1.88","article-title":"The efficacy of low-dose transdermal fentanyl in opioid-na\u00efve cancer patients with moderate-to-severe pain","volume":"30","author":"Kang","year":"2015","journal-title":"Korean J Intern Med"},{"key":"2026070605421660100_ref14","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1248\/bpb.b23-00331","article-title":"Comparison of analgesic efficacy and safety of low-dose transdermal fentanyl and oral oxycodone in opioid-na\u00efve patients with cancer pain","volume":"46","author":"Kozono","year":"2023","journal-title":"Biol Pharm Bull"},{"key":"2026070605421660100_ref15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4212\/cjhp.v61i1.11","article-title":"Safety issues with fentanyl patches require pharmaceutical care","volume":"61","author":"Greenall","year":"2008","journal-title":"Can J Hosp Pharm"},{"key":"2026070605421660100_ref16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1503\/cmaj.150961","article-title":"Safety of fentanyl initiation according to past opioid exposure among patients newly prescribed fentanyl patches","volume":"188","author":"Friesen","year":"2016","journal-title":"CMAJ."}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/873\/68482338\/hyag053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/873\/68482338\/hyag053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:42:23Z","timestamp":1783330943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/7\/873\/8703153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag053","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,5]]}}}